drugset / Trial / NCT03819465
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
Timeline
- Start
- 2018-12-27
- Primary completion
- 2023-05-23
- Completion
- 2026-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Danvatirsen | Antisense oligonucleotide | — | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Oleclumab | Monoclonal antibody | 3000 mg | Intravenous |
| Subject | Rilvegostomig | Other / unclassified | — | Intravenous |
| Subject | Volrustomig | Monoclonal antibody | — | Intravenous |
| Background | Carboplatin | Small molecule | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |
| Background | Pemetrexed | Small molecule | — | Intravenous |